OTCMKTS:QMED

QMed Competitors

$0.0010
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.02
VolumeN/A
Average Volume35,900 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta3.68

Competitors

QMed (OTCMKTS:QMED) Vs. FMS, DVA, SHC, PGNY, TVTY, and OTRK

Should you be buying QMED stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to QMed, including Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), and Ontrak (OTRK).

QMed (OTCMKTS:QMED) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. 35.2% of QMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for QMed and Fresenius Medical Care AG & Co. KGaA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QMed0000N/A
Fresenius Medical Care AG & Co. KGaA19702.35

Fresenius Medical Care AG & Co. KGaA has a consensus target price of $45.00, indicating a potential upside of 16.58%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than QMed.

Profitability

This table compares QMed and Fresenius Medical Care AG & Co. KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QMedN/AN/AN/A
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%

Valuation and Earnings

This table compares QMed and Fresenius Medical Care AG & Co. KGaA's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QMedN/AN/AN/AN/AN/A
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.15$1.34 billion$2.5315.26

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than QMed.

Risk & Volatility

QMed has a beta of 3.68, indicating that its stock price is 268% more volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Summary

Fresenius Medical Care AG & Co. KGaA beats QMed on 7 of the 9 factors compared between the two stocks.

QMed (OTCMKTS:QMED) and DaVita (NYSE:DVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

91.7% of DaVita shares are owned by institutional investors. 35.2% of QMed shares are owned by company insiders. Comparatively, 1.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for QMed and DaVita, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QMed0000N/A
DaVita13102.00

DaVita has a consensus target price of $114.60, indicating a potential upside of 3.45%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than QMed.

Profitability

This table compares QMed and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QMedN/AN/AN/A
DaVita7.32%43.99%5.27%

Valuation and Earnings

This table compares QMed and DaVita's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QMedN/AN/AN/AN/AN/A
DaVita$11.39 billion1.06$810.98 million$5.4020.51

DaVita has higher revenue and earnings than QMed.

Risk & Volatility

QMed has a beta of 3.68, indicating that its stock price is 268% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Summary

DaVita beats QMed on 7 of the 9 factors compared between the two stocks.

QMed (OTCMKTS:QMED) and Sotera Health (NYSE:SHC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for QMed and Sotera Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QMed0000N/A
Sotera Health001003.00

Sotera Health has a consensus target price of $32.75, indicating a potential upside of 25.58%. Given Sotera Health's higher probable upside, analysts clearly believe Sotera Health is more favorable than QMed.

Profitability

This table compares QMed and Sotera Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QMedN/AN/AN/A
Sotera HealthN/AN/AN/A

Valuation and Earnings

This table compares QMed and Sotera Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QMedN/AN/AN/AN/AN/A
Sotera HealthN/AN/AN/AN/AN/A

Summary

Sotera Health beats QMed on 2 of the 2 factors compared between the two stocks.

QMed (OTCMKTS:QMED) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

58.5% of Progyny shares are owned by institutional investors. 35.2% of QMed shares are owned by company insiders. Comparatively, 33.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for QMed and Progyny, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QMed0000N/A
Progyny00603.00

Progyny has a consensus target price of $38.8333, indicating a potential downside of 21.31%. Given Progyny's higher probable upside, analysts clearly believe Progyny is more favorable than QMed.

Profitability

This table compares QMed and Progyny's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QMedN/AN/AN/A
Progyny1.03%7.43%5.04%

Valuation and Earnings

This table compares QMed and Progyny's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QMedN/AN/AN/AN/AN/A
Progyny$229.68 million18.74$-8,570,000.00$0.11448.64

QMed has higher earnings, but lower revenue than Progyny.

Risk & Volatility

QMed has a beta of 3.68, indicating that its stock price is 268% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

Summary

Progyny beats QMed on 7 of the 9 factors compared between the two stocks.

QMed (OTCMKTS:QMED) and Tivity Health (NASDAQ:TVTY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

91.6% of Tivity Health shares are owned by institutional investors. 35.2% of QMed shares are owned by company insiders. Comparatively, 11.8% of Tivity Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for QMed and Tivity Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QMed0000N/A
Tivity Health12502.50

Tivity Health has a consensus target price of $22.1250, indicating a potential downside of 5.12%. Given Tivity Health's higher probable upside, analysts clearly believe Tivity Health is more favorable than QMed.

Profitability

This table compares QMed and Tivity Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QMedN/AN/AN/A
Tivity Health-47.44%128.43%6.11%

Valuation and Earnings

This table compares QMed and Tivity Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QMedN/AN/AN/AN/AN/A
Tivity Health$1.13 billion1.02$-286,820,000.00$2.0211.54

QMed has higher earnings, but lower revenue than Tivity Health.

Risk & Volatility

QMed has a beta of 3.68, indicating that its stock price is 268% more volatile than the S&P 500. Comparatively, Tivity Health has a beta of 2.49, indicating that its stock price is 149% more volatile than the S&P 500.

Summary

Tivity Health beats QMed on 6 of the 9 factors compared between the two stocks.

QMed (OTCMKTS:QMED) and Ontrak (NASDAQ:OTRK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares QMed and Ontrak's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QMedN/AN/AN/A
Ontrak-43.10%N/A-58.54%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for QMed and Ontrak, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QMed0000N/A
Ontrak02302.60

Ontrak has a consensus target price of $47.20, indicating a potential upside of 62.98%. Given Ontrak's higher probable upside, analysts clearly believe Ontrak is more favorable than QMed.

Insider & Institutional Ownership

27.5% of Ontrak shares are owned by institutional investors. 35.2% of QMed shares are owned by company insiders. Comparatively, 58.2% of Ontrak shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares QMed and Ontrak's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QMedN/AN/AN/AN/AN/A
Ontrak$35.10 million14.60$-25,660,000.00($1.15)-25.18

QMed has higher earnings, but lower revenue than Ontrak.

Risk & Volatility

QMed has a beta of 3.68, indicating that its stock price is 268% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.

Summary

Ontrak beats QMed on 5 of the 8 factors compared between the two stocks.


QMed Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$38.60flat$22.61 billion$19.58 billion15.32News Coverage
DaVita logo
DVA
DaVita
1.7$110.78flat$12.12 billion$11.39 billion16.61
Sotera Health logo
SHC
Sotera Health
2.0$26.08flat$7.38 billionN/A0.00News Coverage
Progyny logo
PGNY
Progyny
1.5$49.35flat$4.30 billion$229.68 million448.64Insider Selling
High Trading Volume
Tivity Health logo
TVTY
Tivity Health
1.0$23.32flat$1.15 billion$1.13 billion-2.11
Ontrak logo
OTRK
Ontrak
1.7$28.96flat$512.30 million$35.10 million-17.04
SOC Telemed logo
TLMD
SOC Telemed
1.6$6.62flat$508.24 millionN/A0.00
Viemed Healthcare logo
VMD
Viemed Healthcare
1.1$9.43flat$369.52 million$80.26 million13.10
HemaCare logo
HEMA
HemaCare
0.5$25.31flat$346.52 millionN/A0.00
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.50flat$89.25 millionN/A-2.34Decrease in Short Interest
News Coverage
Cryo-Cell International logo
CCEL
Cryo-Cell International
0.9$9.50flat$74.80 million$31.80 million23.75Gap Up
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.05flat$73.65 millionN/A-0.30Increase in Short Interest
Gap Up
GRNV
GreenVision Acquisition
0.3$10.18flat$73.17 millionN/A0.00Increase in Short Interest
Emmaus Life Sciences logo
EMMA
Emmaus Life Sciences
0.2$1.30flat$63.68 million$1.32 million0.00
PFHOD
Pacific Health Care Organization
0.5$1.25flat$52.48 million$6.80 million0.00Gap Up
CTYX
Curative Biotechnology
0.0$0.11flat$44.56 millionN/A0.00Gap Up
BRTXQ
BioRestorative Therapies
0.0$0.01flat$16.56 million$110,000.00-0.01Gap Down
BioRestorative Therapies logo
BRTX
BioRestorative Therapies
0.6$0.01flat$15.74 million$110,000.000.00Gap Down
PFHO
Pacific Health Care Organization
0.8$1.14flat$14.53 million$7.33 million0.00
GNOW
American Caresource
0.7$0.01flat$124,000.00N/A0.00Gap Down
HYBE
Hybrid Energy
0.0$0.00flat$0.00N/A0.00Gap Up
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.